Assembly Biosciences, Inc.

Is Assembly Biosciences, Inc. overvalued or undervalued?

As of March 28, 2024, Assembly Biosciences, Inc. is considered a risky investment due to its high Price to Book Value of 4.57, negative EV to EBIT and EV to EBITDA ratios, and a negative P/E ratio of -9.31, despite a year-to-date stock return of 41.13% that outperformed the S&P 500, while its long-term performance has significantly underperformed with an 89.36% decline over the past five years.

As of 28 March 2024, the valuation grade for Assembly Biosciences, Inc. has moved from does not qualify to risky, indicating an increased perception of risk associated with the stock. The company appears to be overvalued, given its high Price to Book Value of 4.57 and negative EV to EBIT and EV to EBITDA ratios of -0.75, which suggest that the market may be pricing in expectations that are not supported by current financial performance.<BR><BR>In comparison to its peers, Assembly Biosciences has a P/E ratio of -9.31, while Societal CDMO, Inc. shows a more negative P/E of -10.74, and Outlook Therapeutics, Inc. has a P/E of -0.58. The negative ROE of -147.12% further underscores the challenges the company faces in generating returns. Notably, while the stock has outperformed the S&P 500 on a year-to-date basis with a return of 41.13% compared to 12.22%, its longer-term performance reflects significant underperformance, particularly over the past five years, where it has declined by 89.36% versus the S&P 500's 96.61% gain.

Is Assembly Biosciences, Inc. technically bullish or bearish?

As of September 12, 2025, Assembly Biosciences, Inc. shows a bullish technical trend, supported by strong MACD and moving averages, despite some mildly bearish signals from Dow Theory and OBV, with a year-to-date return of 41.13% outperforming the S&P 500.

As of 12 September 2025, the technical trend for Assembly Biosciences, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators from the MACD, which is bullish on a weekly basis, and the moving averages, which are also bullish daily. Bollinger Bands show a bullish trend weekly and mildly bullish monthly. The KST is bullish for both weekly and monthly periods. However, the Dow Theory indicates a mildly bearish stance weekly, and the OBV shows a mildly bearish trend weekly as well.<BR><BR>In terms of performance, the stock has a year-to-date return of 41.13%, significantly outperforming the S&P 500's return of 12.22%, but it has underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish, driven primarily by the MACD and moving averages.

How big is Assembly Biosciences, Inc.?

As of Jun 18, Assembly Biosciences, Inc. has a market capitalization of 130.45 million and reported net sales of 32.15 million with a net profit of -39.92 million over the latest four quarters. The company's balance sheet shows shareholder's funds of 33.36 million and total assets of 119.97 million.

As of Jun 18, Assembly Biosciences, Inc. has a market capitalization of 130.45 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 32.15 million for the latest four quarters. During the same period, it recorded a net profit of -39.92 million.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 33.36 million and total assets amounting to 119.97 million.

What does Assembly Biosciences, Inc. do?

Assembly Biosciences, Inc. is a biotechnology company focused on developing oral therapeutics for hepatitis B and synthetic live therapeutics for microbiome health. It has a market cap of $130.45 million, with recent net sales of $9 million and a net loss of $9 million.

Overview: <BR>Assembly Biosciences, Inc. is a biotechnology company engaged in developing oral therapeutics for hepatitis B virus (HBV) infection and synthetic live therapeutics aimed at restoring health to a dysbiotic microbiome, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 130.45 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.34 <BR>Return on Equity: -147.12% <BR>Price to Book: 4.81<BR><BR>Contact Details: <BR>Address: 331 OYSTER POINT BLVD., FOURTH FLOOR, SOUTH SAN FRANCISCO CA: 94080 <BR>Tel: 1 212 5544388 <BR>Fax: 1 646 7065101 <BR>Website: https://www.assemblybio.com/

Should I buy, sell or hold Assembly Biosciences, Inc.?

Who are in the management team of Assembly Biosciences, Inc.?

As of March 2022, the management team of Assembly Biosciences, Inc. includes Mr. William Ringo as Non-Executive Independent Chairman and Dr. John McHutchison as President and CEO, along with independent directors Mr. Anthony Altig, Ms. Gina Consylman, Dr. Richard DiMarchi, and Mr. Myron Holubiak.

As of March 2022, the management team of Assembly Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. William Ringo, who serves as the Non-Executive Independent Chairman of the Board.<BR>- Dr. John McHutchison, who is the President, Chief Executive Officer, and a Director.<BR><BR>Additionally, the Board of Directors includes independent directors: Mr. Anthony Altig, Ms. Gina Consylman, Dr. Richard DiMarchi, and Mr. Myron Holubiak.